We are highly interested in studying and exploring the potential of our peptide technology in tissue healing and as a supporting matrix for regeneration.
Our primary focus areas are on regenerating skin, bone, and cartilage tissues.
Skin
The self-assembling peptide technology demonstrated its wound healing potential in both in-vitro and preclinical studies. In the United States, we received 510 (k) approval as a topical wound healing agent for PuraDerm. PuraDerm is indicated for hydrating and managing partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds.
In parallel in Europe, in collaboration with Dr Patricia Rousselle (CNRS), we are investigating the underlying mechanism of our self-assembling peptide technology and how it plays a role in faster re-epithelialization. Our technology has shown matrix properties similar to collagen, with superior adhesion of keratinocytes, followed by quick wound closure.
Patent status:
Ongoing patent application for the peptide-based technology for skin applications covering a vast range of applications (acute and chronic wounds).
Project Status:
Open to collaboration. Open to license out.
Click to collaborate
RADA16 formed a nano-scale scaffold identical to the human extracellular matrix which enhances bone regeneration process. Leveraging this, we are developing a Dental Bone Void Filler (DBVF), which has distinctively shown its efficacy in bone regeneration.
Animal studies and human clinical studies conducted in the United States, demonstrated RADA16's superior efficacy in bone regeneration compared to incumbent products; and emphasised the superiority of RADA16 in fostering the formation of new and healthy bone.
These findings suggest RADA16’s potential for bone regeneration, free of infection and less invasiveness. A pivotal benefit to achieve better patient outcomes but also for dentists, offering the opportunity of higher profits.
The application of RADA16 in dental bone regeneration, stands out as a premium product, both independently and in conjunction with calcium phosphates or other drugs.
Project Status:
Open to collaboration for co-development of DBVF. Possible options: License out with milestone payment, Distribution agreement after product approval, Sell off the patent of RADA16 for DBVF.
Click to collaborate
We developed a proof of concept for full-thickness cartilage regeneration using IEIK13, part of our self-assembling peptide technology pipeline.
Our pre-clinical study, performed in collaboration with Dr Fréderic Mallein Gerin (CNRS), had the aim of restoring full-thickness cartilage defects induced in the femoral condyles of a non-human primate model, the cynomolgus monkey.
The pilot study revealed that IEIK13 acts as a valuable scaffold to support the in-vitro activity of articular chondrocytes and the repair of full-thickness articular cartilage defects when implanted alone or with chondrocytes in vivo.
IEIK13 demonstrates a clear potential as a matrix or scaffold for regenerating cartilage tissue, particularly in addressing microfractures, with a specific focus on osteoarthritis to potentially delay the need for knee replacements.
Project Status:
Open to joint development/license out.
Click to collaborate
